News

Nov 4

2022

PHANES THERAPEUTICS TO PRESENT AT BIOFUTURE™ 2022

Company's CEO to present its innovative oncology pipeline and proprietary bispecific antibody technology platforms SAN DIEGO, Nov. 4, 2022 /PRNewswire/ -- Phanes...
Read More

Oct 14

2022

Phanes Therapeutics announces FDA IND clearance for PT217, an anti-DLL3/anti-CD47 bispecific antibody being developed for patients with small cell lung cancer and other neuroendocrine cancers

SAN DIEGO, Oct. 14, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on oncology, announced today that...
Read More

Aug 23

2022

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT199 for Advanced Solid Tumors

SAN DIEGO, Aug. 23, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More

Aug 2

2022

Phanes Therapeutics’ anti-CD47 antibody patent granted in the US

SAN DIEGO, Aug. 2, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More

Jul 1

2022

Phanes Therapeutics’ PT886 granted Orphan Drug Designation for the treatment of pancreatic cancer by the FDA

SAN DIEGO, June 30, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More

Jun 21

2022

Phanes Therapeutics’ PT217 receives Orphan Drug Designation for small cell lung cancer from the FDA

SAN DIEGO, June 21, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More

Jun 15

2022

Phanes Therapeutics announces FDA IND clearance for PT886, an anti-claudin18.2/anti-CD47 bispecific antibody being developed for patients with gastric, gastroesophageal junction, and pancreatic cancers

SAN DIEGO, June 15, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical...
Read More

Apr 21

2022

Phanes Therapeutics revealed manufacturing validation of its bispecific technology platforms PACbody™ and SPECpair™ at AACR 2022

SAN DIEGO, April 20, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology,...
Read More

Apr 13

2022

Phanes Therapeutics’ anti-CD73 antibody patent granted in the US

SAN DIEGO, April 12, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology,...
Read More

Mar 23

2022

Phanes Therapeutics announces FDA IND clearance for PT199, a next generation monoclonal antibody against human CD73

SAN DIEGO, March 22, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in immuno-oncology...
Read More
1 2 3